EXTREME THROMBOCYTOSIS IN CHRONIC MYELOID LEUKEMIA IN THE ERA OF TYROSINE KINASE INHIBITORS

Federica Sora', Patrizia Chiusolo, Luca Laurenti, Simona Sica, Francesco Autore, Sara Marietti, Sabrina Giammarco, Giuseppe Ausoni, Giuseppe Leone

Risultato della ricerca: Contributo in rivistaArticolo in rivista

6 Citazioni (Scopus)

Abstract

Thrombocytosis is a common feature in chronic myeloproliferative diseases and contributes to an increased incidence of thrombotic and haemorrhagic events during the course of the disease. In chronic myeloid leukemia (CML) however, haemorrhagic and thrombotic complications even with marked thrombocytosis are rare (3% and 1% respectively)[1]. The incidence of thrombocytosis in CML is reported to be around 30 to 50%. Extreme thrombocytosis defined as a platelet count > 1.000 x 109/l is uncommon in CML as well as isolated thrombocytosis and, as reported for other chronic myeloproliferative diseases, acquired von Willebrand syndrome (avWs) might occur [2]
Lingua originaleEnglish
pagine (da-a)2958-2960
Numero di pagine3
RivistaLEUKEMIA & LYMPHOMA
DOI
Stato di pubblicazionePubblicato - 2014

Keywords

  • cml
  • tyrosine kinase inhibitors

Fingerprint

Entra nei temi di ricerca di 'EXTREME THROMBOCYTOSIS IN CHRONIC MYELOID LEUKEMIA IN THE ERA OF TYROSINE KINASE INHIBITORS'. Insieme formano una fingerprint unica.

Cita questo